ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
Quiltman
|
17 |
2.5K |
6 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
17
|
2.5K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
25 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
510
|
117K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
20 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
510
|
117K
|
20
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Paradise Textiles Term Sheet for Exclusive Supply of Fibre
|
|
Quiltman
|
7 |
1.5K |
8 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
7
|
1.5K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
Quiltman
|
22 |
6.8K |
27 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
22
|
6.8K
|
27
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
27 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
510
|
117K
|
27
|
|
ASX - By Stock
|
BRN |
Re:
2024 BrainChip Discussion
|
|
Quiltman
|
5.8K |
2.3M |
65 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
5.8K
|
2.3M
|
65
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
21 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
31 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
510
|
117K
|
31
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Indian Patent Granted for NC6 Nullarbor Lyocell Fibre
|
|
Quiltman
|
6 |
1.5K |
2 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
6
|
1.5K
|
2
|
|
ASX - By Stock
|
CDX |
Re:
will anybody be attending today?
|
|
Quiltman
|
13 |
3.1K |
7 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
13
|
3.1K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAA SHAREHOLDERS 31/5/1924
|
|
Quiltman
|
5 |
2.0K |
29 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
5
|
2.0K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
Quiltman
|
15 |
4.6K |
36 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
15
|
4.6K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
14 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
510
|
117K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Quiltman
|
85 |
20K |
15 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Quiltman
|
85 |
20K |
18 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Quiltman
|
85 |
20K |
20 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Quiltman
|
85 |
20K |
30 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
30
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
16 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
9 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
38 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
38
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
13 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Change of Registered Office and Principal Place of Business
|
|
Quiltman
|
17 |
4.3K |
18 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
17
|
4.3K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
31 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
510
|
117K
|
31
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
31 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
510
|
117K
|
31
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Quiltman
|
1.3K |
349K |
4 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
1.3K
|
349K
|
4
|
|
ASX - By Stock
|
NC6 |
Re:
General Discussion
|
|
Quiltman
|
1.3K |
349K |
8 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
1.3K
|
349K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
20 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
510
|
117K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
25 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
510
|
117K
|
25
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
19 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
141
|
40K
|
19
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
10 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
141
|
40K
|
10
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Nanollose Launches Investor Hub
|
|
Quiltman
|
10 |
2.7K |
5 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
10
|
2.7K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Quiltman
|
58 |
15K |
28 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
58
|
15K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
Quiltman
|
43 |
11K |
29 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
43
|
11K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Quiltman
|
58 |
15K |
27 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
58
|
15K
|
27
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
19 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
141
|
40K
|
19
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
13 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
141
|
40K
|
13
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
15 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
141
|
40K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
65 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
510
|
117K
|
65
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
14 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
141
|
40K
|
14
|
|
ASX - By Stock
|
CDX |
Re:
CDX General discussion 2024
|
|
Quiltman
|
141 |
40K |
11 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
141
|
40K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Quiltman
|
510 |
117K |
30 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
510
|
117K
|
30
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Nanollose Launches Investor Hub
|
|
Quiltman
|
10 |
2.7K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
10
|
2.7K
|
4
|
|
ASX - By Stock
|
NC6 |
Re:
Change the Fabric Investor Steam Interview
|
|
Quiltman
|
4 |
1.0K |
8 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
4
|
1.0K
|
8
|
|
ASX - By Stock
|
NC6 |
Re:
Change the Fabric Investor Steam Interview
|
|
Quiltman
|
4 |
1.0K |
5 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
4
|
1.0K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Quiltman
|
42 |
9.4K |
16 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
16
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Quiltman
|
22 |
5.0K |
2 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
22
|
5.0K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Quiltman
|
86 |
20K |
33 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
20K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Quiltman
|
86 |
20K |
31 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
20K
|
31
|
|
ASX - By Stock
|
NC6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Quiltman
|
22 |
5.0K |
6 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
22
|
5.0K
|
6
|
|